Do you believe the collective data support neoadjuvant chemotherapy or primary debulking surgery for patients with advanced ovarian cancer?

At this time, primary debulking surgery should be applied whenever feasible. However, I think we still do a poor job of selecting patients for PDS versus IDS. We neglect (or do not know) how tumor biology is really affected by surgery. For instance, BRCA-mutated tumors are likely easier to accomplish complete resection (Kim et al., PMID 34256977). But they're also more likely to respond to chemotherapy. Should patients who will have a great response to chemotherapy undergo morbid primary debulki...